Table 6.

Predictors of functional status, damage and inactive disease

Variables	HAQ		JADI-A		JADI-E		Inactive disease
	β (95% CI)	p Value	β (95% CI)	p Value	β (95% CI)	p Value	OR (95% CI)	p Value
Gender—female	−0.03 (−0.2 to 0.2)	0.771	2.0 (−3.1 to 7.1)	0.436	−0.03 (−0,7 to 0.7)	0.937	2.3 (0.2 to 31.3)	0.528
Age at the time of last visit (years)	0.03 (0.0 to 0.04)	<0.0001*	0.3 (0.1 to 0.5)	0.004*	0.02 (−0.0 to 0.1)	0.102	0.9 (0.9 to 1)	0.031*
Age at disease onset (years)	−0.02 (−0.04 to −0.0)	0.021*	−0.9 (−1.4 to −0.3)	0.003*	−0.1 (−0.8 to −0.0)	0.008*	1.4 (1.1 to 1.8)	0.008*
Years of education	−0.02 (−0.1 to 0.0)	0.055	–	–	–	–	–	–
JIA ILAR category†	–	0.4129	–	0.0349*	–	0.5406	–	0.5123
E. oligo	0.04 (−0.3 to 0.4)	0.798	4.5 (−3.2 to 12.2)	0.246	0.5 (−0.6 to 1.5)	0.372	–	–
RF+ poly	0.34 (0.0 to 0.7)	0.036	16.2 (6.8 to 25.6)	0.001*	−0.2 (−1.6 to 1.2)	0.744	8.6 (0.3 to 221.7)	0.194
RF− poly	0.10 (−0.2 to 0.4)	0.501	6.2 (−0.8 to 13.2)	0.081	0.8 (−0.2 to 1.7)	0.124	5.1 (0.2 to 116.9)	0.311
SoJIA	0.05 (−0.4 to 0.5)	0.805	10.2 (1.0 to 19.3)	0.029*	0.3 (−1.0 to 1.7)	0.635	4.2 (0.1 to 314.6)	0.513
ERA	0.2 (−0.1 to 0.5)	0.116	6.4 (−0.8 to 13.6)	0.082	0.7 (−0.3 to 1.7)	0.148	20.4 (0.5 to 853.8)	0.114
PsA	0.1 (−0.5 to 0.6)	0.844	0.2 (19.2 to 19.5)	0.987	0.3 (−1.9 to 2.6)	0.773	–	–
Corticosteroids exposure (yes)	–	–	–	–	1.1 (0.4 to 1.9)	0.002*	–	–
ACPA positive	–	–	–	–	–	–	0.1 (0.0 to 0.7)	0.028*
RF positive	–	–	–	–	–	–	12.9 (0.8 to 200.2)	0.068

*Statistical significance.

†Persistent oligoarthritis used as comparator.

ACPA, anticitrullinated protein antibodies; E. oligo, extended oligoarthritis; ERA, enthesitis-related arthritis; HAQ, Health Assessment Questionnaire; ILAR, International League of Associations for Rheumatology; JADI, Juvenile Arthritis Damage Index; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; RF− poly, rheumatoid factor negative polyarthritis; RF, rheumatoid factor; RF+ poly, rheumatoid factor positive polyarthritis; SoJIA, systemic arthritis.